Topical retinoids for pigmented skin

Journal of Drugs in Dermatology

Volumn 10, Issue 5, 2011, Pages 483-489

  Geria, Aanand N ^a   Lawson, Christina N ^a   Halder, Rebat M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALITRETINOIN; BENZOYL PEROXIDE PLUS CLINDAMYCIN; BEXAROTENE; CLOBETASOL PROPIONATE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; HYDROCORTISONE; HYDROQUINONE; MELANIN; MICROSPHERE; RETINOIC ACID; RETINOID; TAZAROTENE; VITAMIN D DERIVATIVE;

ACNE; ACNE VULGARIS; BURN; CHEMICAL PEEL; CHLOASMA; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CREAM; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DERMATOLOGICAL PROCEDURES; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; EVENING DOSAGE; GEL; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; HYPERTROPHIC SCAR; HYPOPIGMENTATION; KAPOSI SARCOMA; KELOID; MOTTLED FACIAL HYPERPIGMENTATION; PHOTOAGING; PIGMENT DISORDER; POSTINFLAMMATORY HYPERPIGMENTATION; PRACTICE GUIDELINE; PSEUDOFOLLICULITIS BARBAE; PSEUDOFOLLICULITS BARBAE; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SKIN ATROPHY; SKIN COLOR; SKIN EXFOLIATION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PRURITUS; SKIN SCALING; TOPICAL TREATMENT; TREATMENT OUTCOME; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; SKIN DISEASE; SKIN PIGMENTATION;

ADMINISTRATION, CUTANEOUS; HUMANS; HYPERPIGMENTATION; PRACTICE GUIDELINES AS TOPIC; RETINOIDS; SKIN DISEASES; SKIN PIGMENTATION;

EID: 80051609398     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Halder RM. The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol. 1998;39(2 Pt 3):98-103.
2. Kang S, Leyden J, Lowe N, Ortonne JP, et al. Tazarotene Cream for the Treatment of Facial Photodamage. Arch Dermatol. 2001;137:1597-1604.
3. Chandraratna R. Tazarotene - first of a new generation of receptorselective retinoids. Br J Dermatol. 1996;135:18-25.
4. U.S. Census Bureau, 2004. U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin. Available at: http://www.census.gov/ ipc/www/usinterimproj. Date accessed: November 10, 2010.
5. Alexis A, Sergay A, Taylor S. Common dermatologic disorders in skin of color: A comparative practice survey. Cutis. 2007;80:387-394.
6. Halder RM, Grimes P, McLaurin C, Kress M, et al. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32:388-390. (Pubitemid 13021298)
7. Halder RM, Nootheti P. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48:143-148.
8. Grimes PE. Management of Hyperpigmentation in Darker Racial Ethnic Groups. Semin Cutan Med Surg. 2009;28:77-85.
9. Stratigos AJ, Katsambas A. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5:161-168. (Pubitemid 38901545)
10. Morelli J, Norris D. Influence of inflammatory mediators and cytokines in human melanocyte function. J Invest Dermatol. 1993;100:191S-195S. (Pubitemid 23051697)
11. Bulengo-Ransby SM, Griffiths C, Kimbrough-Green C, Finkel LJ, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Eng J Med. 1993;328:1438-1443. (Pubitemid 23143845)
12. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: A double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45-50. (Pubitemid 43189155)
13. Taylor SC. Utilizing Combination Therapy for Ethnic Skin. Cutis. 2007;80:15-20.
14. Kurita M, Kato H, Yoshimura K. A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians. J Plast Reconstr Aesthet Surg. 2009;62:955-963.
15. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
16. Kimbrough-Green CK, Griffiths C, Finkel L, Hamilton TA, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehiclecontrolled clinical trial. Arch Dermatol. 1994;130:727-733. (Pubitemid 24182681)
17. Kligman A, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
18. Grimes P, Kelly A, Torok H, Willis I. Community-Based Trial of a Triple-Combination Agent for the Treatment of Facial Melasma. Cutis. 2006;77:177-184. (Pubitemid 43561381)
19. Cestari TF, Hassun K, Sittart A, De Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007;6:36-39. (Pubitemid 46390328)
20. Chan R, Park K, Lee M, Lee ES, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697-703.
21. Taylor SC, Torok H, Jones T, Lowe N, et al. Efficacy and Safety of a New Triple-Combination Agent for the Treatment of Facial Melasma. Cutis. 2003;72:67-72. (Pubitemid 37229761)
22. Nanda S, Grover C, Reddy B. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. Dermatol Surg. 2004;30:385-388.
23. Kligman A, Fulton J, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99:469-476.
24. Callender VD. Considerations for Treating Acne in Ethnic Skin. Cutis. 2005;76:19-23. (Pubitemid 41290890)
25. Halder RM, Holmes Y, Bridgeman-Shah S, Kligman A. A clinicohistopathologic study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.
26. Jacyk W. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):37-42. (Pubitemid 34036870)
27. Czernielewski J, Poncet M, Mizzi F. Efficacy and Cutaneous Safety of Adapalene in Black Patients Versus White Patients With Acne Vulgaris. Cutis. 2002;70:243-248. (Pubitemid 41757450)
28. Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: A randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci. 2008;49:241-248.
29. Zhu X-J, Tu P, Zhen J, YQ D. Adapalene gel 0.1%: Effective and well tolerated in the topical treatment of acne vulgaris in Chinese patients. Cutis. 2001;68:55-59.
30. Saple DG, Torsekar RG, Pawanarkar V, Dhanalaskshmi UR, et al. An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris. Indian J Dermatol Venereol Leprol. 2004;70:92-95. (Pubitemid 38978007)
31. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol. 2000;43(2 Pt 3):51-54.
32. Guenther L. Tazarotene combination treatments in psoriasis. J Am Acad Dermatol. 2000;43:S36-42. (Pubitemid 30620733)
33. Angelo JS, Kar B, Thomas J. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study. Indian J Dermatol Venereol Leprol. 2007;73:65. (Pubitemid 46348008)
34. Griffiths CEM, Russman A, Majmudar G, Singer R, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med. 1993;329:530-535. (Pubitemid 23232621)
35. Kligman A, Grove GH, R, Leyden J. Topical tretinoin for photo-aged skin. J Am Acad Dermatol. 1986;15:836-859. (Pubitemid 17170790)
36. Griffiths CEM, Goldfarb M, Finkel L, Roulia V, et al. Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: A vehicle-controlled trial. J Am Acad Dermatol. 1994;30(1):76-84. (Pubitemid 24033823)
37. Perry PK, Cook-Bolden FE, Rahman Z, Jones E, et al. Defining pseudofolliculitis barbae in 2001: A review of the literature and current trends. J Am Acad Dermatol. 2002;46(suppl 2):113-119.
38. Halder RM. Pseudofolliculitis barbae and related disorders. Dermatol Clin. 1988;6:407-412.
39. Taylor SC. Enhancing the care and treatment of skin of color, part 1: The broad scope of pigmentary disorders. Cutis. 2005;76:249-255. (Pubitemid 41565663)
40. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, et al. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol. 1985;121:632-635. (Pubitemid 15062716)
41. Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol. 1988;14:1275-1276. (Pubitemid 19000514)
42. Janssen de Limpens AM. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol. 1980;103:319-323.
43. Foy V, Weinkauf R, Whittle E, Basketter DA. Ethnic variation in the skin irritation response. Contact Dermatitis. 2001;45:346-349. (Pubitemid 34056348)
44. Callender VD, Preston N, Osborn C, Johnson L, et al. A Meta- Analysis to Investigate the Relation Between Fitzpatrick Skin Types and Tolerability of Adapalene-Benzoyl Peroxide Topical Gel in Subjects with Mild or Moderate Acne. J Clin Aesthet Dermatol. 2010;3(8):15-19.
45. Peters L, Marriott M, Mukerji B, Indra P, et al. The effect of population diversity on skin irritation. Contact Dermatitis. 2006;55(6):357-363. (Pubitemid 44730155)
46. Callender VD. Acne in ethnic skin: Special considerations for therapy. Dermatol Ther. 2004;17:184-195. (Pubitemid 38656911)
47. Anderson DN, Callender VD, Del Rosso JQ, Tanghetti EA, et al. Topical tazarotene in acne vulgaris: Treatment approaches. Cutis. 2004;74:16-21. (Pubitemid 39462884)
48. Tri-Luma [package insert]. Fort Worth, TX: Galderma Laboratories; 2002.